Innovent Biologics 2025 Annual Results From China Leadership to Global Premier: Innovent's Definitive Path to Value and Growth March 2026 Agenda and Speakers | Business Review and Outlook | Dr. Michael Yu | Founder, Chairman of the Board, CEO | | --- | --- | --- | | R&D Highlight Updates | Dr. Hui Zhou | Chief R&D Officer, Oncology | | | Dr. Lei Qian | Chief R&D Officer, General Biomedicine | | Financials and Summary | Ms. Rachel You | Chief Financial Officer | | Q&A | Management Team | | Confidential Copyr ...

Core Viewpoint - Incyte has announced new executive leadership appointments to enhance its strategic focus and long-term growth plans, reflecting the company's commitment to innovation and operational effectiveness [1][5]. Leadership Appointments - Pablo J. Cagnoni, M.D. has been appointed as President and Global Head of Research and Development, continuing his responsibility for R&D while enhancing strategic planning and operational execution [2]. - Steven Stein, M.D. has been appointed Executive Vice President and Chief Medical Officer, overseeing late-stage development programs across Hematology, Oncology, and Immunology, as well as Global Medical Affairs [3]. - Mohamed Issa, Pharm.D. has been appointed Executive Vice President and Head of U.S. Commercial, integrating U.S. Oncology and Immunology into a single commercial organization to improve operational effectiveness [4]. Strategic Integration - The integration of U.S. commercial teams is aimed at driving effective launch execution and positioning Incyte for long-term success, as stated by CEO Bill Meury [5].

Core Viewpoint - Idorsia Ltd is proposing three candidates for election to its Board of Directors at the upcoming Annual General Meeting, aiming to enhance the Board's expertise in biopharmaceutical innovation and strategic execution [1][4][12]. Group 1: Board Composition - The nominees include Natalia Misciattelli and Gabriel Baertschi as independent members, and André C. Muller as a non-independent member [2][3]. - The proposed Board composition aims to strengthen the company with leaders who have extensive experience in global operations and biopharmaceutical innovation [3][4]. Group 2: Nominee Backgrounds - **Natalia Misciattelli**: CEO of AAVantgarde Bio with over 25 years of experience in biotechnology, focusing on therapeutic platforms and corporate development [5][6]. - **Gabriel Baertschi**: CEO of Grünenthal with more than 20 years in the pharmaceutical industry, known for his expertise in commercial strategy and market expansion [7][8]. - **André C. Muller**: Former CEO of Idorsia, instrumental in the company's development since its inception, bringing deep knowledge of Idorsia's business and strategy [9][10]. Group 3: Re-election of Current Board Members - The Board will also propose the re-election of Jean-Paul Clozel as Chairman, along with independent members Mathieu Simon and Sandy Mahatme, while Bart Filius will not stand for re-election [11][13]. Group 4: Annual General Meeting Details - The Annual General Meeting is scheduled for May 6, 2026, where shareholders are encouraged to register their shares by April 27, 2026, to participate in the voting process [14].

Core Thesis - Regeneron Pharmaceuticals, Inc. (REGN) is viewed positively due to its strong innovation capabilities and the success of its flagship drug, Dupixent, which has expanded its indications and is expected to generate significant revenue [3][4][5] Financial Metrics - As of March 11th, REGN's share price was $774.66, with trailing and forward P/E ratios of 18.68 and 18.05, respectively [1] Product Success - Dupixent is recognized as a blockbuster drug, initially approved for atopic dermatitis and now also used for asthma and other inflammatory diseases, showcasing its efficacy and expanding patient base [3][4] Revenue Generation - The anticipated revenue from Dupixent is expected to be substantial and recurring, allowing Regeneron to reinvest in research and development, thus creating a self-sustaining cycle of innovation [4][5] Pipeline and Innovation - Regeneron has developed a broad pipeline that includes oncology, cardiovascular medicine, and rare diseases, supported by proprietary platforms and scientific expertise, which enhances its competitive position in the biotech sector [4][5] Long-term Growth Potential - The company's strategy leverages the success of Dupixent to fund future innovations, positioning Regeneron for sustained growth and reinforcing its status as a major player in the global biopharmaceutical market [5]

Core Viewpoint - MannKind Corporation has successfully settled the remaining $36.3 million of its 2.50% convertible senior notes, with the settlement completed on March 4, 2026, prior to the maturity date of March 1, 2026 [1] Company Overview - MannKind Corporation is a biopharmaceutical company focused on transforming chronic disease care through innovative, patient-centric solutions [2] - The company specializes in cardiometabolic and orphan lung diseases, developing treatments for serious unmet medical needs such as diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease [2] Product Development Focus - MannKind has deep expertise in drug-device combinations, aiming to deliver therapies that integrate seamlessly into patients' daily lives [3]

Core Viewpoint - Pharming Group N.V. will participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference, scheduled for February 25-26, 2026, highlighting its commitment to engaging with investors and stakeholders in the biopharmaceutical sector [1][2]. Company Overview - Pharming Group N.V. is a global biopharmaceutical company focused on developing and commercializing innovative medicines for patients with rare, debilitating, and life-threatening diseases [3]. - The company is headquartered in Leiden, the Netherlands, with a significant number of employees based in the U.S. [3]. Event Details - Fabrice Chouraqui, CEO, and Anurag Relan, M.D., CMO, will present on February 25 at 12:40 PM ET / 6:40 PM CET, with a live webcast available on Pharming's website [2]. - Investors can schedule one-on-one meetings with Pharming's management team through Investor Relations [2].

Core Insights - Ipsen reported strong financial results for FY 2025, with total sales reaching €3,675.9 million, an increase of 8.1% as reported and 10.9% at constant exchange rates (CER) compared to FY 2024 [2][4] - The company achieved a core operating income of €1,294.1 million, reflecting a growth of 16.7% and a core operating margin of 35.2%, up by 2.6 percentage points [2][4] - Core consolidated net profit increased by 17.6% to €1,009.1 million, with core earnings per share rising to €12.09, a 17.8% increase [2][4] - Ipsen anticipates continued double-digit sales growth for 2026, projecting total sales growth greater than 13.0% at CER, driven by portfolio acceleration and improved outlook for Somatuline [3][5][6] Financial Performance - Total sales for FY 2025 were €3,675.9 million, with growth driven by Oncology (4.1%), Rare Disease (102.5%), and Neuroscience (9.7%) [4] - Somatuline® sales grew by 4.3%, while other products excluding Somatuline achieved double-digit sales growth of 14.2% [4] - Free cash flow for FY 2025 was €1,000.6 million, a 29.2% increase from the previous year [2] Pipeline and Innovation - Ipsen made significant advancements in its pipeline, including multiple regulatory and clinical milestones, and the acquisition of ImCheck Therapeutics [4][15] - Five major regulatory and clinical milestones are expected in 2026, including full data readout for IPN10200 [4][19] - The company initiated several Phase I oncology studies and expanded its immuno-oncology portfolio with the acquisition of ImCheck Therapeutics [15][14] Regulatory and Clinical Developments - In 2025, Ipsen achieved important regulatory milestones, including the acceptance of tovorafenib for review by the EMA and the approval of Cabometyx for advanced neuroendocrine tumors [9][11] - Positive Phase II data for Iqirvo® and IPN10200 were reported, demonstrating promising efficacy and safety profiles [10][12] Environmental, Social, and Governance (ESG) - Ipsen made progress on its sustainability strategy, achieving a 54% reduction in Scopes 1 & 2 greenhouse gas emissions and sourcing 100% of its global electricity from renewable sources [21][25] - The company received an A rating from CDP for environmental actions and achieved gender parity within its Executive Leadership Team [22]

Core Viewpoint - Gilead Sciences is experiencing strong financial performance and growth potential, particularly in its HIV and liver disease segments, supported by a robust pipeline of new products and an optimistic outlook from analysts [1][2][3][4][6]. Financial Performance - Gilead's Q4 2025 earnings report showed total product sales of $7.9 billion, marking a 5% increase year-over-year [2][6]. - For the full year 2025, total sales reached $28.9 billion, reflecting a 1% increase from 2024 [2][6]. - HIV sales specifically grew by 6% year-over-year, driven by the success of the drug Biktarvy and a 47% increase in the HIV prevention portfolio [2][6]. Product Developments - The new HIV prevention injectable, Yeztugo, has surpassed coverage goals and is gaining market share [3][6]. - Gilead's pipeline includes up to 10 ongoing and potential new launches through 2027, with four commercial launches planned for 2026 [3][6]. - The liver business reported a 6% growth, attributed to the adoption of Livdelzi for primary biliary cholangitis [4][6]. - Trodelvy, an oncology product, also demonstrated positive momentum with a 6% growth in 2025, supported by favorable Phase results [4][6]. Analyst Ratings - BMO Capital has maintained an "Outperform" rating for Gilead, raising the price target from $150 to $160, indicating confidence in the company's future performance [1][6].

Core Insights - The BIOSeedin Winter Innovation Partnering Summit was held on January 11, 2026, in San Francisco, focusing on the China Asset Showcase to promote international presentation of Chinese innovative drugs and facilitate licensing cooperation [1] Group 1: Event Overview - The summit attracted over 500 industry representatives from more than 10 countries and regions, including multinational corporations, pharmaceutical and biotechnology companies, and leading investment institutions [2] - More than 300 individual meetings and 18 special tours of innovative Chinese biotechs were organized, reflecting a dynamic atmosphere of enthusiastic exchanges and strong collaboration intentions [2] Group 2: Industry Discussions - Three cross-border roundtables were held, where seasoned business development professionals and industry leaders discussed oncology, cardio-renal and metabolic diseases, and autoimmune diseases [3] - Key topics included differentiated national therapies for high-incidence cancers reshaping Chinese R&D in oncology, AI-accelerated clinical trials in cardio-renal and metabolic diseases, and multidimensional priorities for Sino-foreign cooperation in autoimmune diseases [3] - The 18 Chinese biotechs showcased high-quality assets in cutting-edge areas such as bispecific antibodies, ADCs, and molecular glues, aligning with industry hotspots and demonstrating successful R&D achievements in niche sectors [3] Group 3: Future Directions - The summit facilitated the gathering of global cutting-edge information, activated inter-regional and inter-sectoral cooperation, and created a professional bridge for the internationalization of Chinese innovative drugs [4] - BIOSeedin plans to leverage the value of its platform, organize high-quality industry events, and collaborate with global partners to explore investment opportunities and jointly shape the future of biopharmaceutical innovation [4]

Core Insights - The BIOSeedin Winter Innovation Partnering Summit focused on showcasing Chinese innovative drugs and facilitating international collaboration in the biopharmaceutical sector [1][4] - The event attracted over 500 industry representatives from more than 10 countries, highlighting its global reach and the strong interest in Chinese biotech innovations [2] Industry Engagement - The summit featured over 300 one-on-one matchmaking meetings and 18 special roadshows by Chinese biotechs, indicating a high level of engagement and collaboration among participants [2] - Three cross-border roundtable forums addressed key therapeutic areas such as oncology, cardio-renal-metabolic diseases, and autoimmune diseases, showcasing the depth of discussion and expertise present [3] Innovation and R&D - Chinese biotechs presented high-quality assets in advanced fields like bispecific antibodies, antibody-drug conjugates (ADCs), and molecular glues, reflecting significant R&D achievements in niche sectors [3] - Insights shared during the forums included the impact of differentiated therapies on oncology R&D in China and the role of AI in accelerating clinical trials in cardio-renal-metabolic diseases [3] Future Outlook - BIOSeedin aims to continue leveraging its platform to foster global partnerships and explore investment opportunities in biopharmaceutical innovation [4] - The organization plans to host more high-quality industrial events to further enhance collaboration and innovation in the sector [4]